TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVANYSE
$32.03
↓ -0.6%Jul 17 close · end-of-day
Price
1Y↑ +100.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$37.8B
Enterprise Value
$36.6B
P/E
23.9
P/S
2.7
P/B
4.6
EV/EBITDA
11.1
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$14.1B
Net Income (TTM)
$1.6B
Free Cash Flow (TTM)
—
Gross Margin
63.9%
Operating Margin
16.2%
Net Margin
11.1%
ROE
19.0%
ROIC
32.3%
Debt / Equity
0.3
Net Cash
$1.1B
Return 1Y
+96.4%
Company profile
Teva Pharmaceutical Industries Limited sells generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. Its products in the central nervous system, pain, respiratory, and oncology areas include Copaxone for the treatment of relapsing forms of multiple sclerosis. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
- CEO
- Kåre Schultz
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 36,800
- Website
- tevapharm.com
Management & directors
- Shields MatthewEVP, Global Operations
- Kalif Eliyahu SharonEVP, Chief Financial Officer
- Francis Richard DPresident and CEO
- Lippman EvanEVP, Business Development
- Weiss AmirChief Accounting Officer
- Daniell RichardExec. VP, European Commercial
- Sabag MarkSee "Remarks"
- Fox ChristineEVP, Head of U.S. Commercial
- Hughes Eric ASee "Remarks"
- Jover PlacidSee "Remarks"
- Savage BrianInterim Chief Legal Officer
- Mcavoy David R.EVP, Chief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
TEVA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$4.0B↑ +2.3%
Diluted EPS$0.31↑ +72.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $16.7B | $15.9B | $14.9B | $15.8B | $16.5B | $17.3B |
| Gross profit | $7.7B | $7.6B | $7.0B | $7.6B | $8.1B | $8.9B |
| Operating income | -$3.6B | $1.7B | -$2.2B | $433.0M | -$303.0M | $2.2B |
| Net income | -$4.0B | $417.0M | -$2.4B | -$559.0M | -$1.6B | $1.4B |
| Diluted EPS | -$3.64 | $0.38 | -$2.20 | -$0.50 | -$1.45 | $1.21 |
| Operating cash flow | $1.2B | $798.0M | $1.6B | $1.4B | $1.2B | $1.6B |
| Free cash flow | $638.0M | $236.0M | $1.0B | — | — | — |
| Gross margin | 46.4% | 47.8% | 46.7% | 48.2% | 48.7% | 51.8% |
| Operating margin | -21.4% | 10.8% | -14.7% | 2.7% | -1.8% | 12.5% |
| Net margin | -24.0% | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2B | $4.3B | $4.2B | $3.9B | $4.2B | $4.5B | $1.5B | $4.0B |
| Gross profit | $2.0B | $2.1B | $2.1B | $1.9B | $2.1B | $2.3B | $2.7B | $2.0B |
| Operating income | -$5.0M | -$51.0M | -$29.0M | $519.0M | $455.0M | $882.0M | $301.0M | $652.0M |
| Net income | -$846.0M | -$437.0M | -$217.0M | $214.0M | $282.0M | $433.0M | $481.0M | $369.0M |
| Diluted EPS | -$0.75 | -$0.39 | -$0.19 | $0.18 | $0.24 | $0.37 | $0.42 | $0.31 |
| Operating cash flow | $103.0M | $693.0M | $575.0M | -$105.0M | $227.0M | $369.0M | $1.2B | -$40.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 48.6% | 49.6% | 50.2% | 48.2% | 50.3% | 51.4% | 177.0% | 49.5% |
| Operating margin | -0.1% | -1.2% | -0.7% | 13.3% | 10.9% | 19.7% | 20.1% | 16.4% |
| Net margin | -20.3% | -10.1% | -5.1% | 5.5% | 6.8% | 9.7% | 32.1% | 9.3% |
Company news
Jul 15, 2026
Jul 13, 2026
- 7d agoDeckers Brands Announces Conference Call to Review First Quarter Fiscal 2027 Earnings Resultsfinance.yahoo.com
- 7d agoTeva (TEVA) Stock Looks Discounted On Cash Flow Yet Fair On Earningsfinance.yahoo.com
- 7d agoIs JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?finance.yahoo.com
- 7d agoTeva (TEVA) Reports Promising Vitiligo Trial Results And Moves Anti IL 15 Drug Forwardfinance.yahoo.com
Jul 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | Shields Matthew· EVP, Global Operations | Sale | 9,989 | $32.19 | $321,546.91 | filing |
| 2026-06-11 | Kalif Eliyahu Sharon· EVP, Chief Financial Officer | Sale | 106,563 | $34.10 | $3.6M | filing |
| 2026-06-05 | Francis Richard D· President and CEO | Sale | 6,153 | $34.35 | $211,355.55 | filing |
| 2026-06-05 | Crane Rosemary A | Option exercise | 14,492 | — | — | filing |
| 2026-06-05 | Elstein Amir | Option exercise | 14,492 | — | — | filing |
| 2026-06-05 | LIEBERMAN GERALD M | Option exercise | 14,492 | — | — | filing |
| 2026-06-05 | Nisen Perry | Option exercise | 14,492 | — | — | filing |
| 2026-06-05 | Satchi-Fainaro Ronit | Option exercise | 14,492 | — | — | filing |
| 2026-06-05 | Zaks Tal Zvi | Option exercise | 14,492 | — | — | filing |
| 2026-06-05 | Francis Richard D· President and CEO | Option exercise | 13,043 | — | — | filing |
| 2026-06-05 | MIGNONE ROBERTO | Option exercise | 14,492 | — | — | filing |
| 2026-06-05 | BARER SOL J | Option exercise | 21,739 | — | — | filing |
| 2026-06-05 | Lichtenstein Chen | Option exercise | 14,492 | — | — | filing |
| 2026-06-03 | Shields Matthew· EVP, Global Operations | Sale | 16,195 | $32.87 | $532,329.65 | filing |
| 2026-06-03 | Shields Matthew· EVP, Global Operations | Option exercise | 16,195 | — | — | filing |
| 2026-05-14 | Kalif Eliyahu Sharon· EVP, Chief Financial Officer | Sale | 153,251 | $35.61 | $5.5M | filing |
| 2026-05-14 | Lippman Evan· EVP, Business Development | Sale | 35,912 | $35.58 | $1.3M | filing |
| 2026-05-14 | Lippman Evan· EVP, Business Development | Sale | 5,746 | $35.58 | $204,466.81 | filing |
| 2026-05-14 | Lippman Evan· EVP, Business Development | Option exercise | 74,008 | — | — | filing |
| 2026-05-14 | Lippman Evan· EVP, Business Development | Option exercise | 11,841 | — | — | filing |
| 2026-05-06 | Weiss Amir· Chief Accounting Officer | Sale | 10,679 | $36.00 | $384,444.00 | filing |
| 2026-05-05 | Daniell Richard· EVP, Europe Commercial | Sale | 30,000 | $35.40 | $1.1M | filing |
| 2026-05-01 | Sabag Mark· See "Remarks" | Sale | 144,180 | $34.99 | $5.0M | filing |
| 2026-04-30 | Fox Christine· EVP, U.S. Commercial | Sale | 21,258 | $35.31 | $750,619.98 | filing |
| 2026-03-17 | Sabag Mark· See "Remarks" | Sale | 62,102 | $30.14 | $1.9M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.